LINEAGE CELL THERAPEUTICS LCTX 深 沪
已收盘 08-08 16:00:00 美东时间
0.9844
+0.034
+3.53%
华盛通- 最 高0.9999
- 今 开0.955
- 成交量 65.80万股
- 最 低 0.953
- 昨 收 0.9508
- 总市值 2.24亿
- 52周最高 1.21
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.3651
- 委 比 -95.65%
- 总股本 2.28亿
- 历史最高 3.132
- 量 比 0.56
- 振 幅 4.93%
- 历史最低 0.3651
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lineage Cell Therapeutics Announced The First Chronic Spinal Cord Injury Patient Has Been Treated In The Company's DOSED Clinical Study, Evaluating A New Parenchymal Spinal Delivery System
The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery system, a novel delivery device developed to deliver OPC1 directly to the site of injury in patients with spinal cord
08-04 20:10
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
Lineage Therap Reports Promising OpRegen Study Results
An announcement from Lineage Therap ( ($LCTX) ) is now available. Lineage Cell ...
06-24 02:55
Lineage's OpRegen Shows +9 Letter BCVA Gains At 3 Years With Extensive Cell Coverage In Phase 1/2a Trial For Geographic Atrophy
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atrophy (GA) lesion siteEvidence of retinal structural improvement persisted out to 3 yearsAnatomical and
06-23 19:09
Lineage Cell Therapeutics Q1 EPS $(0.02) Beats $(0.03) Estimate, Sales $1.50M Miss $1.87M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 50 percent increase over losses of $(0.04) per share
05-14 05:22
Earnings Scheduled For May 13, 2025
Companies Reporting Before The Bell • Endeavour Silver (NYSE:EXK) is estimated ...
05-13 16:32
Lineage Cell Therapeutics Says RG6501 Phase 1/2a Clinical Study 36 Month Results To Be Featured At Clinical Trials At The Summit 2025
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that 36-month results from
05-12 20:09
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers BioSig Technologies (NASDAQ:BSGM) stock moved upwards by 18.9% to $0.6...
04-17 05:05
美股大行评级 | Tigress Financial：维持爱彼迎"买入"评级，目标价从195美元升至200美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107588488073326592.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持ProQR Therapeutics(PRQR)"买入"评级，目标价从10美元升至12美元</p> <p>• Oppenheimer：上调内克塔治疗(NKTR)评级至"跑
03-17 10:10
Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies
Lineage Cell Therapeutics, Inc. (LCTX) has disclosed a new risk, in the Economy...
03-12 14:01
